News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
credentis ag Extends Its Leadership Into the Field of Dentistry
7/22/2013 2:01:20 PM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
July 22, 2013 -- credentis ag elected at the annual general assembly Dr. Michael Peetz as a new member of the
board of directors, expanding its expertise into the field of dentistry. Peetz, born in 1957, studied
Pharmacy in Munich, Germany and Austin, Texas. After an extended stay to pursue his research in
San Francisco, he joined the pharmaceutical company Hoechst (now Sanofi-Aventis) in the clinical
research department. Between 1990 – 2008, Dr. Michael Peetz held several positions at Geistlich
Biomaterials—including CEO beginning in 1998. He was responsible for developing Geistlich
Biomaterials, becoming number one globally in bone and tissue regeneration in the field of
dentistry. From 2008 - 2012 he was CEO of Camlog Biotechnologies in Basel, Switzerland, an
international leader in implant dentistry with a worldwide distribution network.
Dr. Peetz was also co-founder and director of the Osteology Foundation, in Lucerne, Switzerland,
a foundation that deals with research and education in regenerative dentistry. Since 2012, he has
been President of Digital Dental Life AG, specializing in the licensing of their Web technology to
the Dental Campus Association for the online training of dentists in the field of implantology.
Curodont™ and Curolox™ technologies
The patented Curolox™ technology is based on peptides self-assembling into a matrix, triggering a
biomimetic mineralisation and repair mechanism. The breakthrough is the basis for several
innovative credentis products.
Curodont™ Repair provides dentists with a non-invasive option for natural mineralisation rather
than classical repair of carious lesions. Applied to an early lesion, Curodont™ Repair forms a scaffold
within the lesion to allow new hydroxyapatite crystals to form and grow. Ideally, the lesion will
mineralise within several weeks. This effect is observed in a growing number of patients both in
clinical studies and daily practice settings. Curodont™ Repair shows tremendous potential in the
treatment of early dental caries.
Curodont™ Protect uses the Curolox™ technology to protect the tooth surface from acid attack and
to treat unpleasant tooth sensations. According to CEO, Dominik Lysek, “Curodont™ Protect has its
main benefit in prophylaxis and in the treatment of dentin hypersensitivity.”
The clinical data obtained in proof-of-concept clinical studies present a milestone for credentis,
showing the successful in-depth treatment of tooth decay. credentis, with its regenerative product
line, launches a trend towards prevention and early treatment. The ultimate goal is to prevent
caries through the use of its regenerative solutions, avoiding frequent recalls by dentists and
About credentis ag
credentis ag is headquartered in the Technopark, Aargau, Switzerland. credentis has won multiple
awards as well as support from organizations such as Genilem. Public grants include Swiss National
Fund, Aargauer Forschungsfond and the Medical Technologies IKC together with the University of
Dominik Lysek, CEO; Michael Hug, CTO; and Tobias Feger, CBO, have a strong track record in
medical technology, marketing and networking in the dental industry. credentis board members Dr.
Werner Berner, Dr. Michael Peetz and Dr. Erich Platzer (chairman), contribute their pharma,
medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.